Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for DXVX (180400:KRX), powered by AI.
DXVX is currently trading at ₩2,610. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for DXVX on Alpha Lenz.
DXVX's P/E ratio is -8.6.
“DXVX trades at a P/E of -8.6 (undervalued) with modest ROE of -53.8%.”
Ask for details →Dx & Vx Co., Ltd. is a dynamic entity within the biotechnology and pharmaceutical sectors. The company is primarily involved in the development and manufacturing of diagnostics and vaccines, playing a crucial role in global health. Its product portfolio includes a range of innovative solutions designed to detect and combat infectious diseases, thereby addressing significant public health challenges. Dx & Vx Co., Ltd. is notable for its focus on cutting-edge technologies and collaborations, seeking to enhance its offerings through strategic alliances and research partnerships. This focus positions the company as a key player in the advancement of medical solutions aimed at disease prevention and management. In the financial markets, Dx & Vx Co., Ltd. is recognized for its potential impact on healthcare outcomes globally, particularly through its contributions to both preventive and responsive medical treatments. Its operations are crucial not only in opening new avenues for medical intervention but also in supporting global initiatives towards health security and disease eradication.
“DXVX trades at a P/E of -8.6 (undervalued) with modest ROE of -53.8%.”
Ask for details →DXVX (ticker: 180400) is a company listed on KRX in the Unknown sector (Unknown). Market cap is $249.0B.
The current price is ₩2,610 with a P/E ratio of -8.58x and P/B of 2.65x.
ROE is -53.82% and operating margin is -82.85%. Annual revenue is $29.4B.